[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-metastases-from-extra-cranial-solid-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-metastases-from-extra-cranial-solid-tumors":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,68,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100491235","early-phase-1-mefamp-for-imaging-system-a-amino-acid-transport-in-primary-and-metastatic-brain-tumors-100491235",false,"NCT05676489","MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors","Inclusion Criteria for all cohorts:\n\n1. 18 years of age or older at the time of enrollment\n2. Females with childbearing potential must have a negative urine human chorionic gonadotropin (hCG) test on the day of procedure or a serum hCG test within 48 hours prior to the administration MeFAMP.\n3. Must have a life expectancy greater than 12 weeks.\n\nExclusion Criteria for all cohorts:\n\n1. Use of an investigational drug for any indication within 3 months prior to the imaging study.\n2. Pregnancy or breast feeding\n3. Inability to complete the PET scans.\n4. Significant renal or hepatic dysfunction (estimated glomerular filtration rate (GFR) \\\u003C 60 mL\u002Fmin)\n5. Any condition which may interfere with ability to participate in or complete all study-related activities as assessed by the study team.\n\n6.4.9.3. Inclusion criteria specific to Dosimetry Cohort\n\n1. Normal complete metabolic profile (CMP) and cell blood count (CBC) with differential at baseline.\n2. Normal ECG at baseline.\n\nExclusion criteria specific to Dosimetry Cohort\n\n1\\) Major medical problems (e.g. renal, hepatic, inflammatory) that could interfere with biodistribution of MeFAMP as assessed by the study team.\n\nInclusion Criteria specific to HGG Cohort\n\n1. Grade III or Grade IV glioma previously treated with radiation therapy\n2. Standard of care contrast-enhanced MRI showing an enhancing lesion at least 1-cm in maximum dimension that is equivocal or suspicious for recurrent glioma.\n3. Eastern Cooperative Oncology Group (ECOG) performance score of 2 or better\n\nInclusion Criteria specific to Metastasis Cohort\n\n1. At least one brain metastasis from melanoma, lung cancer (small or non-small cell), or breast cancer measuring at least 1-cm in maximum dimension on contrast-enhanced MRI\n2. Plan for stereotactic radiation therapy within 2 weeks of initial MeFAMP-PET\u002FMRI scan.\n3. ECOG performance score of 2 or better\n\nInclusion of Women and Minorities\n\nPatients 18 years of age or older will be eligible for study participation. No other discriminatory factors, including age, sex, or ethnic background will be used to determine eligibility. Every effort will be made to ensure that minorities are recruited for study participation.",true,"ALL","18 Months","89 Years",{"count":20,"type":21},28,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","This first-in-human study will establish the human safety and radiation dosimetry of the system A amino acid transport substrate, (R)-3-\\[F-18\\]fluoro-2-methyl-2-(methylamino)propanoic acid (\\[F-18\\]MeFAMP), for positron emission tomography (PET) imaging of primary and metastatic brain tumors. This study will include 3 cohorts: healthy volunteers for whole body dosimetry estimates (n=6-8, Dosimetry Cohort), patients undergoing evaluation for recurrent high grade glioma after radiation therapy (n=10, high grade glioma (HGG) Cohort), and patients with brain metastases from extra-cranial solid tumors before and after radiation therapy (n=10, Metastasis Cohort). Exploratory assessment of the diagnostic accuracy of MeFAMP for distinguishing recurrent\u002Fprogressive brain tumors from radiation-related treatment effects will also be performed for subsequent trial design. The study will complete accrual and safety assessment in the Dosimetry Cohort before recruiting for the HGG and Metastasis Cohorts.",[27,28,29],"Healthy Volunteers","Recurrent Glioma","Brain Metastases From Extra-cranial Solid Tumors","NOT_YET_RECRUITING","2026-08-17",{"date":33,"type":34},"2026-08-20","ACTUAL",{"date":36,"type":21},"2027-04-01",{"date":38,"type":21},"2029-08-30",{"name":40,"class":41},"University of Alabama at Birmingham","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":42},"100650934","preliminary-clinical-feasibility-study-of-a-medical-device-enabling-brain-access-using-microbubble-enhanced-sonication-100650934","NCT07754006","Preliminary Clinical Feasibility Study of a Medical Device Enabling Brain Access Using Microbubble-Enhanced Sonication","Cerebral Access Using Microbubble Potentiated Sonication: Initial Study","CAMPSIS","Inclusion Criteria:\n\n1. Age: ≥18 years old.\n2. Performance Status: Karnofsky Performance Score (KPS) ≥ 70%.\n3. Tumor Characteristics:\n\n   1. Patient with an expansive intra-cerebral tumor showing enhancement after gadolinium injection on MRI (T1-weighted images, with and without gadolinium contrast).\n   2. Tumor radiologically classified as:\n\n      * Recurrent High-Grade glioma (excluding prosthetic material), or a brain metastasis from extracranial solid primary.\n      * Measuring at least 25-30 mm in the longest axis.\n      * In both cases, Surgery is not required as a first-line option. However, the target lesion must be considered technically operable (non-eloquent location)\n   3. In the case of brain metastases, multifocal disease is allowed, provided that additional metastases are smaller to 20 mm, not neurologically threatening, and do not require surgery. Cases of leptomeningeal invasion are not allowed.\n   4. Tumor should not exhibit signs of rapid progression or acute neurological compromise requiring urgent intervention. Rapid progression is defined as a ≥25% increase in contrast-enhancing tumor volume within 4 weeks, associated with mass effect or new edema. Acute neurological compromise includes any newly developed or worsening neurological deficit (e.g., motor weakness, aphasia), seizures refractory to antiepileptics, decreased level of consciousness (Glasgow Coma Scale (GCS) \\\u003C13), or signs of intracranial hypertension.\n4. Operability and Location:\n\n   * Target Tumor is deemed operable by the neurosurgeon and is located in a non-eloquent area (e.g., excluding brainstem or regions associated with critical motor or speech function).\n   * Tumor must be located in the cortical or subcortical regions, at least 20 mm beneath the inner skull surface to ensure accessibility to the TheraOne intervention.\n5. In case of brain metastasis, extracerebral disease must be absent or at least controlled, defined as:\n\n   * A Positron Emission Tomography (PET) scan performed within 6 weeks showing resolution of hyperintensity, or\n   * Stable disease on two consecutive imaging assessments\n   * And oligometastatic state, defined as ≤3 extracerebral lesions.\n6. Blood Pressure Stability : Systolic ≤180 mmHg, Diastolic ≤100 mmHg at screening.\n7. Coagulation Stability :\n\n   * Platelets ≥80.10 9 \u002FL\n   * Prothrombin time (PT) ≤14 sec\n   * Partial thromboplastin time (PTT) ≤36 sec\n   * International Normalized Ratio (INR) ≤1.3\n8. Prior and ongoing treatments\n\n   * Prior systemic anticancer treatments are allowed provided that all the following conditions are met:\n\n     * The patient has a clinically stable neurological status at inclusion.\n     * There is no ongoing ≥ Grade 2 neurological toxicity attributable to prior or ongoing systemic treatment.\n     * Corticosteroid dose is stable or decreasing for at least 7 days prior to inclusion.\n   * The following minimum wash-out periods prior to sonication must be respected:\n\n     * Immunotherapy (anti-PD-1, anti-PD-L1, anti-CTLA-4): ≥ 7 days before sonication.\n     * Nitrosourea-containing chemotherapy (BCNU, CCNU): ≥ 6 weeks before sonication.\n     * Targeted therapies - lung cancer (EGFR, ALK, ROS1, MET TKIs): Wash-out corresponding to 5 terminal half-lives, capped at a maximum of 7 days, provided neurological stability and absence of recent treatment initiation or dose escalation.\n     * Targeted therapies - melanoma (BRAF and\u002For MEK inhibitors): A short pragmatic wash-out of approximately 5-7 days, not strictly based on pharmacokinetic half-life, may be applied provided neurological status is stable and no ≥ Grade 2 neurological toxicity is present.\n     * Anti-angiogenic therapy (bevacizumab):\n\n   A minimum interval of 7 days prior to sonication is required.\n   * Antibody-drug conjugates (ADCs): A wash-out of 7 days prior to sonication is required. ADC treatment must be ongoing (not recently initiated), with no ≥ Grade 2 toxicity, particularly neurological or hematological.\n   * Antiplatelet and anticoagulant agents: Must be discontinued according to the following minimum intervals prior to sonication:\n\n     * antiplatelet agents: ≥ 7 days\n     * vitamin K antagonists: ≥ 7 days\n     * direct oral anticoagulants (NOACs): ≥ 72 hours\n     * heparin-derived compounds: ≥ 48 hours\n\n       * Prior brain radiotherapy is allowed provided it was completed ≥ 12 weeks before sonication\n9. Renal Function: Estimated glomerular filtration rate (eGFR) ≥30 mL\u002Fmin\u002F1.73m².\n10. MRI \\& CT Compatibility: Patient must be able to complete high-density CT and MRI studies, including contrast-enhanced imaging.\n11. Procedure Feasibility :\n\n    * Willingness to undergo partial head shaving to allow proper ultrasound transmission\n    * Ability to maintain stable seated position during procedure.\n12. Negative Serum Pregnancy Test (within 7 days before first treatment) for women of childbearing potential.\n13. Contraceptive Use: Women of childbearing potential and men with partners of childbearing potential must agree to use a highly effective (\\\u003C1% failure rate per year) approved contraceptive method during procedure and for 6 months post- procedure. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.\n14. Signed Informed Consent Form.\n15. Patients must be affiliated or beneficiary to a social security system\n\nExclusion Criteria:\n\n1. Tumor-Related Exclusions:\n\n   * Tumor imaging features suggestive of:\n\n     * Acute mass effect with ≥5 mm midline shift or basal cistern effacement.\n     * Severe peritumoral edema causing acute intracranial hypertension or compression of critical structures.\n     * Hemorrhagic transformation or necrosis with a high risk of rupture.\n   * Tumor morphology or imaging findings that preclude the ability to sonicate the tumor volume, including:\n\n     * Significant tumor volume outside the treatment envelope.\n     * Tumor volume exceeding the maximum allowed sonication volume (currently 110 ccs at the treatment volume level).\n     * Concerns about adequate tumor coverage by sonication based on tumor morphology should be discussed with the Sponsor.\n2. Vascular \\& Hemorrhagic Conditions:\n\n   * Cerebrovascular disease history:\n\n     * Untreated arteriovenous malformation (AVM).\n     * Untreated or unstable cerebral aneurysm.\n   * Acute hemorrhage or cystic lesions:\n\n     * Evidence of acute intracranial hemorrhage.\n     * Presence of a cyst within the region of interest (ROI).\n   * MRI or clinical findings of:\n\n     * Active or chronic infections\u002Finflammatory processes.\n     * Acute or chronic hemorrhages, lobar microbleeds, siderosis, amyloid angiopathy, or macro-hemorrhages.\n     * Intracranial thrombosis, vascular malformation, cerebral aneurysm, or vasculitis.\n3. Cardiovascular \\& Systemic Conditions:\n\n   * Unstable cardiac disease or hemodynamic status.\n   * Uncontrolled severe hypertension (systolic \\>180 mmHg, diastolic \\>100 mmHg).\n4. Anticoagulation \\& Bleeding Risks:\n\n   * Use of medications that increase bleeding risk:\n\n     * Antiplatelet agents (e.g., aspirin, clopidogrel) within 7 days prior to treatment.\n     * Anticoagulants (e.g., warfarin, dabigatran, apixaban, heparin) within specified washout periods:\n\n       * Oral vitamin K inhibitors: 7 days\n       * Non-Vitamin K antagonist oral anticoagulants (NOACs) (e.g., rivaroxaban, apixaban): 72 hours\n       * Heparin-derived compounds: 48 hours\n   * Abnormal coagulation profile: Platelets \\\u003C80,000 109\u002FL, PT \\>14, PTT \\>36, INR \\>1.3.\n   * History of bleeding disorder, coagulopathy, or spontaneous hemorrhage.\n5. Neurological \\& Psychiatric Conditions:\n\n   * Active seizures (\\>1 per week) despite medication, as BBB opening could worsen seizures.\n   * Active drug\u002Falcohol disorder, increasing seizure, infection, or compliance risks.\n   * Known positive Human Immunodeficiency Virus (HIV) status, which may increase BBB permeability and lead to encephalitis.\n   * Potential blood-borne infections that could increase risk of meningitis or brain abscess.\n6. Prior treatments incompatible with study participation\n\n   * Any immunotherapy administered within 7 days prior to sonication.\n   * Any nitrosourea-containing chemotherapy administered within 6 weeks prior to sonication.\n   * Any targeted therapy not meeting the wash-out and stability criteria described above.\n   * Any antibody-drug conjugate administered within 7 days prior to sonication or associated with ongoing ≥ Grade 2 toxicity.\n   * Any experimental therapy or investigational medicinal product not discontinued ≥ 30 days prior to sonication.\n   * Brain radiotherapy completed \\\u003C 12 weeks prior to sonication\n7. Imaging \\& Gadolinium Contraindications:\n\n   * Severe claustrophobia or inability to remain supine for 2 hours.\n   * Body habitus incompatible with CT or MRI scanner limits\n   * Known allergy(ies) or hypersensitivity to gadolinium contrast agents.\n   * MRI-incompatible implanted device (e.g., pacemaker, defibrillatore, cochlear implant)\n   * Ferromagnetic foreign body\n8. Contraindications to Microbubble Use:\n\n   * Hypersensitivity to sulfur hexafluoride microbubbles or any excipient\n   * History of severe allergic reactions (anaphylaxis) to contrast agents.\n   * Right-to-left cardiac shunt or embolization risk.\n   * Severe pulmonary hypertension or unstable cardiac conditions (e.g. unstable ischemic heart disease, acute coronary syndrome within the previous 30 days).\n   * Uncontrolled systemic hypertension,\n   * Adult respiratory distress syndrome (ARDS)\n   * Any SmPC-listed contraindication\n9. Contraindications\u002F constraints from associated non-experimental devices :\n\n   * Ultrasound gel :\n\n     * Known hypersensitivity to any component of the ultrasound gel used during the procedure\n   * Cervical collar (PATRIOT) , contraindications per IFU\n\n     * Compromised airway,\n     * Known severe spinal deformity (e.g., ankylosing spondylitis),\n     * Penetrating trauma injuries (cervical).\n   * Positionning chair :\n\n     * Inability to maintain a stable seated position for the duration of the procedure.\n10. Other Procedure-Related Exclusions:\n\n    * Presence of metallic implants (e.g., clips in skull\u002Fbrain) interfering with sonication.\n    * Scalp infection at target site\n11. Psychological, Social \\& Legal Factors:\n\n    * Mental health disorders or social\u002Fgeographical barriers that could affect CI compliance.\n    * Patients under legal protection, guardianship, or deprived of liberty.\n12. Pregnancy \\& Breastfeeding:\n\n    * Pregnant or breastfeeding women, or those planning pregnancy during the CI and 6 months after.","18 Years",{"count":53,"type":21},6,[55],"PHASE1","CAMPSIS is a preliminary feasibility study of the TheraOne medical device (IIb). TheraOne is an active, non-invasive medical device intended to deliver transcranial FUS in combination with intravenous microbubbles in order to transiently and locally induce the BBB permeability.\n\nThis study aims to evaluate the safety of cerebral sonication (TheraOne) in the management of patients with recurrent grade 4 glioma (wild-type IDH, technically resectable) or brain metastases originating from an extracranial solid tumor.\n\nPatients enrolled in the study will undergo a single sonication session during a protocol visit and will be monitored for up to 30 days after the sonication through the various scheduled protocol visits.\n\nBlood samples will be collected at the start of the study, during the sonication, and during the post-sonication follow-up visit for all patients enrolled in the study.",[58,29],"Recurrent Grade 4 Glioma","2026-08-06",{"date":61,"type":34},"2026-08-10",{"date":63,"type":21},"2026-09",{"date":65,"type":21},"2027-10",{"name":67,"class":41},"Gustave Roussy, Cancer Campus, Grand Paris",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":42},"100603105","phase-2-stereotactic-radiation-for-growingchanging-brain-metastases-with-same-day-radiation-planning-and-treatment-with-margin-reduction-100603105","NCT07132190","Stereotactic Radiation for Growing\u002FChanging Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction","A Double-Blind Phase II Randomized Study of Adaptively Delivered LINAC-Based Stereotactic Radiation for Volatile Brain Metastases With Same-Day Planning and Margin Reduction","Inclusion Criteria:\n\n1. Participants must have a biopsy proven solid malignancy with at least one intact, residual or recurrent, intracranial lesion radiographically consistent with or pathologically proven to be a brain metastasis meeting one of the following criteria:\n\n   1. Growth of 1.0mm per week or more, on average, based on the two most recent brain MRIs preceding study enrollment\n   2. Abutment, to within 1.0cm, of a region of intracranial edema\n   3. Proximity (within 5.0cm) to a surgical cavity created within 30 days of enrollment\n   4. Proximity (within 5.0cm) to another source of physical displacement\n2. Age of at least 18 years\n3. Karnofsky performance status of at least 60\n4. Estimated survival of at least 3-6 months in the opinion of the enrolling clinician and\u002For study PI\n5. Ability to understand and the willingness to sign a written informed consent document by either ink on paper or a DF\u002FHCC approved eConsent medium\n\nExclusion Criteria:\n\n1. Participants who cannot tolerate a brain MRI\n2. Patients who cannot receive gadolinium\n3. Participants with end stage renal disease\n4. Participants with widespread, definitive leptomeningeal disease\n5. Pregnant women are excluded from this study because of the potential deleterious effects of gadolinium on the developing fetus. Because there is an unknown but potential risk for adverse events in nursing infants, women who are breastfeeding are not eligible for this study as well",{"count":76,"type":21},60,[78],"PHASE2","The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval between radiation planning (radiation mapping) and radiation treatment. The intent of this shorter time interval is to increase the likelihood that the brain metastases being treated remain fully within the high-dose radiation fields.\n\nParticipants will be randomized to receive brain-directed stereotactic radiation with a 1mm margin or 0mm margin, have their simulation\u002Fradiation planning imaging on the same day that brain-directed stereotactic radiation is delivered, and have repeat simulation\u002Fradiation planning scans during the course of treatment if more than 2-3 days have elapsed since the most recent scans.",[81,82,83,29],"Brain Metastases, Adult","Brain Tumor - Metastatic","Brain Metastases From Non-small Cell Lung Cancer (NSCLC)",[85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110],"Brain Mets","Brain Metastases","Brain-directed stereotactic radiation","Brain radiation","Volatile Brain Metastases","Intracranial lesion","SRS","SRT","RANO","PTV","Planning Target Volume","Local Recurrence","Radiation Necrosis","Adaptive","VMAT","Volumetric Modulated Arc Therapy","Margin","Volatile","Rapid","Growth","Shift","neurocognitive","quality of life","survival","same day","randomized","RECRUITING","2026-03-17",{"date":114,"type":34},"2026-03-19",{"date":116,"type":34},"2025-12-30",{"date":118,"type":21},"2029-09",{"name":120,"class":41},"Ayal A. Aizer, MD",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":135,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":42},"100602997","phase-2-prophylactic-anti-seizure-medication-vs-no-anti-seizure-medication-for-patients-with-primary-motor-cortex-brain-metastases-100602997","NCT07130786","Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases","A Phase II Randomized Open-Label Trial of Levetiracetam for Prevention of Seizures in Patients With Brain Metastases in Primary Motor Cortex","Inclusion Criteria:\n\n1. Participants must have a biopsy proven solid malignancy with at least one intracranial lesion radiographically consistent with or pathologically proven to be a brain metastasis located in the primary motor cortex measuring 0.5 cm or larger in maximal unidimensional size\n2. Age of at least 18 years\n3. Karnofsky performance status of at least 60\n4. Estimated survival of at least 3-6 months in the opinion of the enrolling clinician and\u002For study PI\n5. Ability to understand and the willingness to sign a written informed consent document by either ink on paper or a DF\u002FHCC approved eConsent medium\n\nExclusion Criteria:\n\n1. Participants with prior seizures as this is a study for seizure naïve patients\n2. Participants with an allergy to levetiracetam as levetiracetam is the prophylactic anti-seizure medication under study\n3. Participants concurrently taking (i.e. at enrollment) an ASM for non-seizure indications at clinically relevant doses (gabapentin 1800 mg\u002Fday or higher, pregabalin 300 mg\u002F day or higher, lamotrigine 150 mg\u002F day or higher, valproic acid 1000 mg\u002F day or higher, topiramate 200 mg\u002F day or higher, carbamazepine 200 mg\u002F day or higher, oxcarbazepine 300 mg\u002F day or higher, primidone 100 mg\u002Fday or higher) because use of these medications could bias the study toward the null\n4. Participants who cannot tolerate a magnetic resonance imaging (MRI) study of the brain, which is required to determine the presence of and follow the course of brain metastases under study\n5. Participants who cannot receive gadolinium as MRI of the brain with contrast is required\n6. Participants with end stage renal disease due to risk of nephrogenic systemic fibrosis in this patient population after exposure to gadolinium-based contrast agents\n7. Participants with widespread, definitive leptomeningeal disease given that leptomeningeal disease and brain metastases are different entities\n8. Pregnant women are excluded from this study because levetiracetam crosses the placenta. In addition, the potential deleterious effects of gadolinium on the developing fetus are not completely known\n9. Women who are breastfeeding are excluded from this study because levetiracetam enters breast milk. In addition, the potential deleterious effects of gadolinium in breast milk remain unknown",{"count":129,"type":21},150,[78],"This is a randomized trial for patients with brain metastases in the primary motor cortex who have not had seizures to receive either the prophylactic anti-seizure medication levetiracetam (also known by its trade name Keppra) or proceed with standard of care management, which does not currently include prophylactic levetiracetam. Patients who enroll to this trial will be randomized to receive prophylactic levetiracetam or not receive prophylactic levetiracetam.",[133,134,83,81,29],"Seizures","Primary Motor Cortex",[136,137,138,139,140,141,142,143,144,145,146,91,92,147,148,107,149,150,151,152,153,154,155,156,157,158,159],"brain metastases","seizure","levetiracetam","seizure-naive","keppra","motor","primary motor cortex","motor strip","prophylaxis","Anti-Seizure Medication","ASM","necrosis","local recurrence","focal aware","focal impaired awareness","focal to bilateral tonic clonic","generalized","focal preserved consciousness","focal impaired consciousness","FPC","FIC","FTBC","tonic","clonic",{"date":114,"type":34},{"date":162,"type":34},"2025-12-23",{"date":164,"type":21},"2030-02",{"name":120,"class":41}]